跳至主要内容
临床试验/NCT02844153
NCT02844153Unknown不适用

Metformin Use in Chronic Kidney Disease: The CKD-Met Study

Hospices Civils de Lyon1 个研究点 分布在 1 个国家目标入组 1,000 人开始时间: 2014年3月最近更新:
适应症

试验速览

阶段
不适用
入组人数
1,000
试验地点
1
主要终点
Percentage of patients receiving metformin

研究概览

简要总结

Metformin is the most widely prescribed oral treatment for diabetes, and the only one that showed a survival benefit.

Yet, there is no consensus on the optimal dose and withdrawal of metformin in chronic kidney disease (CKD) patients.

The aim of the study is to describe the use and side-effects of metformin in CKD patients in routine practice.

研究设计

研究类型
Observational
观察模型
Cohort

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 18 years old or more
  • Type 2 diabetes
  • Seen by a nephrologist (consultation or hospitalization) between March 2014 and March 2020 in the Department of Nephrology, Lyon Sud university hospital, France

排除标准

  • On-going treatment by dialysis
  • Kidney transplantation
  • Type 1 diabetes
  • Missing data (metformin treatment)

结局指标

主要结局

Percentage of patients receiving metformin

时间窗: every January 1st up to 2020

metformin use during chronic kidney disease. Percentage of patients receiving metformin will be recorded.

次要结局

  • starting time of insulin(every January 1st up to 2020)
  • CKD stages(every January 1st up to 2020)
  • Dose of metformin(every January 1st up to 2020)
  • Doses of oral antidiabetes medications(every January 1st up to 2020)
  • Occurence of reasons for non-prescription of metformin(every January 1st up to 2020)
  • occurrence of lactic acidosis(every January 1st up to 2020)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验